eli lilly's tirzepatide is the leader in weight loss sector Lilly Launches Self-Pay Vials of for Patients With Obesity Eli Lilly's Tirzepatide Shows Promise

The duration of follow-up varied among the studies, ranging from 12 to 40 months, with an average duration of 29 months

This dual mechanism is why tirzepatide produces greater weight loss in clinical trials and why the dosing numbers look completely different

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Zepbound has been shown to be a possible treatment for obstructive sleep apnea

Finally, our findings offer a more comprehensive assessment compared with another analysis that produced indirect estimates between tirzepatide and semaglutide 2.0 mg using data solely from two RCTs [57]